Century Therapeutics (NASDAQ:IPSC) Announces Earnings Results

Century Therapeutics (NASDAQ:IPSC) issued its earnings results on Tuesday. The company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.08, RTT News reports. The business had revenue of $0.79 million during the quarter, compared to analyst estimates of $0.47 million. Century Therapeutics had a negative return on equity of 60.60% and a negative net margin of 6,434.23%. During the same period in the previous year, the company posted ($0.55) EPS.

Century Therapeutics Stock Performance

IPSC stock traded down $0.04 on Friday, hitting $1.42. 162,919 shares of the company’s stock were exchanged, compared to its average volume of 261,123. Century Therapeutics has a 12-month low of $1.14 and a 12-month high of $5.51. The firm has a 50 day moving average price of $1.52 and a two-hundred day moving average price of $2.23. The stock has a market cap of $120.30 million, a P/E ratio of -0.79 and a beta of 1.41.

Analyst Ratings Changes

IPSC has been the subject of several recent research reports. HC Wainwright reduced their price target on Century Therapeutics from $9.00 to $5.00 and set a “buy” rating for the company in a research report on Wednesday. Chardan Capital reduced their price target on Century Therapeutics from $17.00 to $11.00 and set a “buy” rating for the company in a research report on Thursday. Finally, Rodman & Renshaw initiated coverage on Century Therapeutics in a research report on Thursday, August 8th. They issued a “buy” rating and a $6.00 price target for the company. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $11.60.

Century Therapeutics Company Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.